Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence

被引:130
作者
Hernes, E [1 ]
Fosså, SD
Berner, A
Otnes, B
Nesland, JM
机构
[1] Norwegian Radium Hosp, Dept Clin Canc Res, N-0310 Oslo, Norway
[2] Norwegian Radium Hosp HF, Dept Pathol, Oslo, Norway
[3] Baerum Hosp, Dept Surg, Baerum, Norway
关键词
prostatic neoplasms/receptor; epidermal growth factor/receptor; erbB-2/receptor; erbB-3;
D O I
10.1038/sj.bjc.6601536
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Novel palliative strategies for patients with androgen-independent prostate cancer (AIPC) include targeting the epidermal growth factor receptor (EGFR) family. The aim of the present study was to investigate intrapatient changes of EGFRs during the development of AIPC. In total, 106 symptomatic AIPC patients were identified in whom prostatic biopsies (adenocarcinoma) were available both before the start of androgen deprivation (PRTR biopsy) and after the development of AIPC (AIPC biopsy). All four known subgroups of the EGFR family were determined by immunohistochemistry (IHC): c-erbB-I (EGFR), c-erbB-2 (HER2/neu), c-erbB-3 (HER3) and c-erbB-4 (HER4). Moderate to strong membrane-specific staining was recorded semiquantitatively (< 10% vs ≥ 10% = IHC stained tumour cells: 'negative' vs 'positive' staining). The medical records were reviewed for clinical variables. During the development of AIPC, intrapatient changes occurred in two opposite directions for each of the four EGFRs: negativity changed to positivity, and vice versa, statistically significant only for the increase of c-erbB-I expression (P = 0.001). The c-erbB-2 expression in the AIPC biopsy was associated with a significantly shorter survival from the time of the AIPC biopsy (P = 0.029). Our results support ongoing therapeutic attempts of EGFR inhibition in subgroups of patients with prostate cancer. Further research is needed to understand the function of EGFRs in this malignancy.
引用
收藏
页码:449 / 454
页数:6
相关论文
共 28 条
[1]   Growth factors and their receptors: New targets for prostate cancer therapy [J].
Barton, J ;
Blackledge, G ;
Wakeling, A .
UROLOGY, 2001, 58 (2A) :114-122
[2]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[3]   A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase [J].
Craft, N ;
Shostak, Y ;
Carey, M ;
Sawyers, CL .
NATURE MEDICINE, 1999, 5 (03) :280-285
[4]  
Di Lorenzo G, 2002, CLIN CANCER RES, V8, P3438
[5]   Independent prognostic significance of Her-2 oncoprotein expression in pNO prostate cancer undergoing curative radiotherapy [J].
Fosså, A ;
Lilleby, W ;
Foss, SD ;
Gaudernack, G ;
Torlakovic, G ;
Berner, A .
INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (01) :100-105
[6]   Androgen-independent prostate cancer -: The clinical problem of a growing pelvic tumour [J].
Hernes, E ;
Fosså, SD ;
Skovlund, E .
ACTA ONCOLOGICA, 2003, 42 (07) :749-755
[7]   Hormone-resistant prostate cancer with symptomatic pelvic tumours:: patient survival and prognostic factors [J].
Hernes, EH ;
Linja, M ;
Fosså, SD ;
Visakorpi, T ;
Berner, A ;
Winderen, M ;
Koivisto, PA .
BJU INTERNATIONAL, 2000, 86 (03) :240-247
[8]   Regulation of epidermal growth factor receptor internalization by G protein-coupled receptors [J].
Kim, J ;
Ahn, S ;
Guo, R ;
Daaka, Y .
BIOCHEMISTRY, 2003, 42 (10) :2887-2894
[9]   EXPRESSION OF THE C-ERBB-2 (HER-2/NEU) ONCOPROTEIN IN HUMAN PROSTATIC-CARCINOMA [J].
KUHN, EJ ;
KURNOT, RA ;
SESTERHENN, IA ;
CHANG, EH ;
MOUL, JW .
JOURNAL OF UROLOGY, 1993, 150 (05) :1427-1433
[10]  
Lee H, 2001, CANCER RES, V61, P4467